Description

Elifor (desvenlafaxine succinate) tablets with prolonged release 50 mg. №28

Ingredients

Active ingredient: Desvenlafaxine succinate. Inactive ingredients: Mannitol, hypromellose, ethylcellulose, and other excipients.

Dosage

Recommended dosage: 50 mg once daily, with or without food. Swallow the tablet whole with water, do not crush or chew.

Indications

Elifor tablets are indicated for the treatment of major depressive disorder (MDD) in adults.

Contraindications

Do not use Elifor tablets if you are allergic to desvenlafaxine or if you are taking or have taken within the last 14 days any monoamine oxidase inhibitors (MAOIs).

Directions

Take Elifor tablets exactly as prescribed by your healthcare provider. Do not discontinue the medication abruptly without consulting your doctor.

Scientific Evidence

Desvenlafaxine succinate, the active ingredient in Elifor tablets, is a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by restoring the balance of certain natural substances in the brain. Clinical trials have shown that desvenlafaxine is effective in reducing the symptoms of depression and improving overall mood in patients with MDD.

Additional Information

It is important to follow your healthcare provider’s instructions carefully when taking Elifor tablets. Inform your doctor about any other medications you are taking to avoid potential drug interactions. If you experience any severe side effects or allergic reactions, seek medical attention immediately.

Pharmacological Effects: Desvenlafaxine succinate acts by inhibiting the reuptake of serotonin and norepinephrine, thereby prolonging the effects of these neurotransmitters in the brain. This mechanism helps alleviate symptoms of depression and improve mood.

Clinical Trials: Clinical studies have demonstrated the efficacy of desvenlafaxine in the treatment of major depressive disorder. In a randomized controlled trial published in the Journal of Clinical Psychiatry, desvenlafaxine was found to be significantly more effective than a placebo in reducing depressive symptoms.